Keith W. Pfeil, the Chief Operating Officer and Chief Financial Officer of Globus Medical Inc. (NYSE:GMED), has recently executed a series of stock transactions, according to a recent SEC filing. On January 10, Pfeil sold a total of 14,167 shares of the company's Class A Common Stock in two separate transactions, amounting to approximately $1.25 million. The shares were sold at prices ranging from $88.17 to $89.17, with the stock trading near its 52-week high of $90.48. InvestingPro data shows the company's strong market position with a market capitalization of $11.95 billion and an impressive 55% return over the past year.
In addition to the sales, Pfeil also exercised stock options to acquire 14,167 shares at prices between $49.65 and $53.27, totaling approximately $733,560. Following these transactions, Pfeil now holds no shares of Globus Medical directly.
These transactions were conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan for buying or selling stock, helping to avoid concerns of insider trading.
In other recent news, Globus Medical has reported an impressive 6.6% increase in sales for Q4 2024, reaching approximately $657 million. The company's full-year sales for 2024 also saw a significant rise of 60.6% to approximately $2.52 billion. Looking ahead to 2025, Globus Medical projects revenues between $2.66 billion and $2.69 billion, and earnings per share in the range of $3.40 to $3.50. These figures are approximately 1% higher than the midpoints of current Street estimates.
Canaccord Genuity and Truist Securities have maintained their Buy and Hold ratings on Globus Medical respectively, while BofA Securities upgraded the company's stock to Neutral, following a successful integration of NuVasive (NASDAQ:NUVA). Furthermore, RBC Capital Markets has projected a positive outlook for the Medical (TASE:PMCN) Supplies & Devices sector for 2025, featuring Globus Medical in their smid-cap selections.
Analysts from Roth/MKM, BTIG, and Morgan Stanley (NYSE:MS) also see potential growth for Globus Medical, specifically citing the expansion of robotics. These recent developments reflect the company's strong performance trajectory and promising outlook for the upcoming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.